{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:22:27Z","timestamp":1768004547299,"version":"3.49.0"},"reference-count":38,"publisher":"Akademiai Kiado Zrt.","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["AMicr"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Infection is one of the most feared hospital-acquired complications. Infusion therapy is frequently administered through a central line. Infusions facilitating bacterial growth may be a source of central line-associated bloodstream infections. On the other hand, medications that kill bacteria may protect against this kind of infection and may be used as a catheter lock.<\/jats:p><jats:p>In this study, we examined the impact of amiodarone on bacterial growth. Amiodarone is used for controlling cardiac arrhythmias and can be administered as an infusion for weeks. Standard microbiological methods have been used to study the growth of laboratory strains and clinical isolates of <jats:italic>Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa<\/jats:italic>, <jats:italic>Escherichia coli<\/jats:italic>, <jats:italic>Klebsiella pneumoniae<\/jats:italic>, and multidrug-resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> in amiodarone. The minimum inhibitory concentration (MIC) of amiodarone was determined. Bacterial growth from in use amiodarone syringes and giving sets was also investigated.<\/jats:p><jats:p>Most examined strains were killed within 1 min in amiodarone. The other strains were killed within 1 h. The MICs of amiodarone were &lt;0.5\u201332 \u03bcg\/mL.<\/jats:p><jats:p>Amiodarone infusion is unlikely to be responsible for bloodstream infections as contaminating bacteria are killed within 1\u2009h. Amiodarone may also protect against central line infections if used as a catheter lock.<\/jats:p>","DOI":"10.1556\/030.2020.01144","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T07:43:32Z","timestamp":1661759012000},"page":"133-137","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":9,"title":["Amiodarone that has antibacterial effect against human pathogens may represent a novel catheter lock"],"prefix":"10.1556","volume":"67","author":[{"given":"Balazs","family":"Ittzes","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Medical School, University of Pecs, Pecs, Hungary"},{"name":"Department of Anaesthesia and Intensive Therapy, North Devon District Hospital, Barnstaple, Devon, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Szentkiralyi","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Medical School, University of Pecs, Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szabo","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Therapy, Medical School, University of Pecs, Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan Z.","family":"Batai","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Medical School, University of Pecs, Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ors","family":"Gyorffy","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Medical School, University of Pecs, Pecs, Hungary"},{"name":"Department of Anaesthesiology and Intensive Therapy, St. Rafael Hospital, Zalaegerszeg, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamas","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Therapy, Medical School, University of Pecs, Pecs, Hungary"},{"name":"Department of Anaesthesiology and Intensive Therapy, St. Rafael Hospital, Zalaegerszeg, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-4973","authenticated-orcid":true,"given":"Istvan","family":"Batai","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Therapy, Medical School, University of Pecs, Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Kerenyi","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Medical School, University of Pecs, Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"B1","series-title":"Eur J Anaesthesiol","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/00003643-199907000-00001","article-title":"The impact of drugs used in anaesthesia on bacteria","volume":"16","author":"Batai I","year":"1999","unstructured":"Batai I, Kerenyi M, Tekeres M. The impact of drugs used in anaesthesia on bacteria. Eur J Anaesthesiol 1999; 16: 425\u201340.1045787410.1097\/00003643-199907000-00001"},{"key":"B2","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"426","article-title":"Postsurgical infections associated with extrinsically contaminated intravenous anesthetic agent: California, Illinois, Maine, and Michigan 1990","volume":"39","author":"Centers for Disease Control (CDC)","year":"1990","unstructured":"Centers for Disease Control (CDC). Postsurgical infections associated with extrinsically contaminated intravenous anesthetic agent: California, Illinois, Maine, and Michigan 1990. MMWR Morb Mortal Wkly Rep 1990; 39: 426\u20137."},{"key":"B3","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/cid\/cir138","article-title":"Summary of recommendations: guidelines for the prevention of intravascular catheter-related infections","volume":"52","author":"O\u2019Grady NP","year":"2011","unstructured":"O\u2019Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, . Summary of recommendations: guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52: 1087\u201399.2146701410.1093\/cid\/cir138"},{"key":"B4","series-title":"JAMA Intern Med","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1001\/jamainternmed.2013.9763","article-title":"Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system","volume":"173","author":"Zimlichman E","year":"2013","unstructured":"Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, . Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013; 173: 2039\u201346.2399994910.1001\/jamainternmed.2013.9763"},{"key":"B5","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"S340","DOI":"10.1093\/cid\/ciu670","article-title":"Advances in prevention and management of central line-associated bloodstream infections in patients with cancer","volume":"59","author":"Raad I","year":"2014","unstructured":"Raad I, Chaftari AM. Advances in prevention and management of central line-associated bloodstream infections in patients with cancer. Clin Infect Dis 2014; 59: S340\u20133.2535262810.1093\/cid\/ciu670"},{"key":"B6","series-title":"J Hosp Infect","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhin.2017.11.002","article-title":"Mortality risk factors among non-ICU patients with nosocomial vascular catheter-related bloodstream infections: a prospective cohort study","volume":"99","author":"Saliba P","year":"2018","unstructured":"Saliba P, Hornero A, Cuervo G, Grau I, Jimenez E, Garc\u00eda D, . Mortality risk factors among non-ICU patients with nosocomial vascular catheter-related bloodstream infections: a prospective cohort study. J Hosp Infect 2018; 99: 48\u201354.2912834610.1016\/j.jhin.2017.11.002"},{"key":"B7","series-title":"J Hosp Infect","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhin.2014.06.007","article-title":"Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices","volume":"88","author":"Worth LJ","year":"2014","unstructured":"Worth LJ, Slavin MA, Heath S, Szer J, Grigg AP. Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices. J Hosp Infect 2014; 88: 48\u201351.2506301310.1016\/j.jhin.2014.06.007"},{"key":"B8","series-title":"JAMA","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jama.298.11.1312","article-title":"Prescribing amiodarone: an evidence-based review of clinical indications","volume":"298","author":"Vassallo P","year":"2007","unstructured":"Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298: 1312\u201322.1787842310.1001\/jama.298.11.1312"},{"key":"B9","series-title":"J Hosp Infect","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jhin.2011.07.002","article-title":"Impact of medications on bacterial growth in syringes","volume":"79","author":"Kerenyi M","year":"2011","unstructured":"Kerenyi M, Borza Z, Csontos C, Ittzes B, Batai I. Impact of medications on bacterial growth in syringes. J Hosp Infect 2011; 79: 265\u20136.2186493910.1016\/j.jhin.2011.07.002"},{"key":"B10","series-title":"Anesth Analg","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2146\/ajhp110715","article-title":"The growth of bacteria in intravenous glyceryl trinitrate and in sodium nitroprusside","volume":"89","author":"Batai I","year":"1999","unstructured":"Batai I, Kerenyi M, Tekeres M. The growth of bacteria in intravenous glyceryl trinitrate and in sodium nitroprusside. Anesth Analg 1999; 89: 1570\u20132.1058965110.2146\/ajhp110715"},{"key":"B11","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-Tenth Edition. CLSI document M07\u2013A10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2016.09.011","author":"CLSI","year":"2015","unstructured":"CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-Tenth Edition. CLSI document M07\u2013A10. Wayne PA: CLSI; 2015. Clinical and Laboratory Standard Institute.10.1016\/j.jclinane.2016.09.011"},{"key":"B12","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1128\/AAC.00355-19","article-title":"The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program","volume":"63","author":"Diekema DJ","year":"2019","unstructured":"Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, . The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2019; 63: e00355\u201319. https:\/\/doi.org\/10.1128\/aac.00355-19.3101086210.1128\/AAC.00355-19"},{"key":"B13","series-title":"Biol Pharm Bull","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1248\/bpb.b18-00821","article-title":"Evaluation of in vitro bactericidal activity of 1.5% olanexidine gluconate, a novel biguanide antiseptic agent","volume":"42","author":"Seyama S","year":"2019","unstructured":"Seyama S, Nishioka H, Nakaminami H, Nakase K, Wajima T, Hagi A, . Evaluation of in vitro bactericidal activity of 1.5% olanexidine gluconate, a novel biguanide antiseptic agent. Biol Pharm Bull 2019; 42: 512\u201315.3056810610.1248\/bpb.b18-00821"},{"key":"B14","series-title":"Appl Biochem Biotechnol","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1385\/ABAB:87:3:165","article-title":"Amiodarone interactions with membrane lipids and with growth of Bacillus stearothermophilus used as a model","volume":"87","author":"Rosa SM","year":"2000","unstructured":"Rosa SM, Antunes-Madeira MC, Jurado AS, Madeira VV. Amiodarone interactions with membrane lipids and with growth of Bacillus stearothermophilus used as a model. Appl Biochem Biotechnol 2000; 87: 165\u201375.1098222710.1385\/ABAB:87:3:165"},{"key":"B15","series-title":"J Pharmacol Exp Ther","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1124\/jpet.300.1.195","article-title":"Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone","volume":"300","author":"Courchesne WE","year":"2002","unstructured":"Courchesne WE. Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone. J Pharmacol Exp Ther 2002; 300: 195\u20139.1175211610.1124\/jpet.300.1.195"},{"key":"B16","series-title":"Am J Respir Cell Mol Biol","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1165\/rcmb.2007-0217OC","article-title":"Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a postendosomal level","volume":"39","author":"Stadler K","year":"2008","unstructured":"Stadler K, Ha HR, Ciminale V, Spirli C, Saletti G, Schiavon M, . Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a postendosomal level. Am J Respir Cell Mol Biol 2008; 39: 142\u20139.10.1165\/rcmb.2007-0217OC"},{"key":"B17","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/jac\/dku091","article-title":"The clinically approved drugs amiodarone, dronedarone, and verapamil inhibit filovirus cell entry","volume":"69","author":"Gehring G","year":"2014","unstructured":"Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, . The clinically approved drugs amiodarone, dronedarone, and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014; 69: 2123\u201331.2471002810.1093\/jac\/dku091"},{"key":"B18","series-title":"Trends Mol Med","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molmed.2015.12.005","article-title":"Progression of Ebola therapeutics during the 2014-2015 outbreak","volume":"22","author":"Mendoza EJ","year":"2016","unstructured":"Mendoza EJ, Qiu X, Kobinger GP. Progression of Ebola therapeutics during the 2014-2015 outbreak. Trends Mol Med 2016; 22: 164\u201373.2677463610.1016\/j.molmed.2015.12.005"},{"key":"B19","series-title":"J Biol Chem","doi-asserted-by":"publisher","first-page":"28831","DOI":"10.1074\/jbc.M303300200","article-title":"Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis","volume":"278","author":"Gupta SS","year":"2003","unstructured":"Gupta SS, Ton VK, Beaudry V, Rulli S, Cunningham K, Rao R. Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. J Biol Chem 2003; 278: 28831\u20139.1275419710.1074\/jbc.M303300200"},{"key":"B20","series-title":"Infect Dis Clin North Am","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.idc.2017.05.007","article-title":"Prevention of central line-associated bloodstream infections","volume":"31","author":"Bell T","year":"2017","unstructured":"Bell T, O\u2019Grady NP. Prevention of central line-associated bloodstream infections. Infect Dis Clin North Am 2017; 31: 551\u20139.2868721310.1016\/j.idc.2017.05.007"},{"key":"B21","series-title":"Int J Antimicrob Agents","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ijantimicag.2017.06.013","article-title":"Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients","volume":"50","author":"Norris LB","year":"2017","unstructured":"Norris LB, Kablaoui F, Brilhart MK, Bookstayer PB. Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients. Int J Antimicrob Agents 2017; 50: 308\u201317.2868987810.1016\/j.ijantimicag.2017.06.013"},{"key":"B22","series-title":"Clin J Am Soc Nephrol","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2215\/CJN.01270210","article-title":"Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis","volume":"5","author":"Landry DL","year":"2010","unstructured":"Landry DL, Braden GL, Gobeille SL, Haessler SD, Vaidya CK, Sweet SJ. Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 2010; 5: 1799\u2013804.2059568910.2215\/CJN.01270210"},{"key":"B23","series-title":"Clin J Am Soc Nephrol","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2215\/CJN.11291113","article-title":"Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients","volume":"9","author":"Moore CL","year":"2014","unstructured":"Moore CL, Besarab A, Ajluni M, Soi V, Peterson EL, Johnson LE, . Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients. Clin J Am Soc Nephrol 2014; 9: 1232\u20139.2497087410.2215\/CJN.11291113"},{"key":"B24","series-title":"J Vasc Access","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5301\/jva.5000681","article-title":"Any use for alternative lock solutions in the prevention of catheter-related blood stream infections?","volume":"18","author":"Labriola L","year":"2017","unstructured":"Labriola L, Pochet JM. Any use for alternative lock solutions in the prevention of catheter-related blood stream infections?. J Vasc Access 2017; 18: 34\u20138.2829705510.5301\/jva.5000681"},{"key":"B25","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1093\/jac\/dku182","article-title":"Adverse effects associated with ethanol catheter lock solutions: a systematic review","volume":"69","author":"Mermel LA","year":"2014","unstructured":"Mermel LA, Alang N. Adverse effects associated with ethanol catheter lock solutions: a systematic review. J Antimicrob Chemother 2014; 69: 2611\u20139.2489143110.1093\/jac\/dku182"},{"key":"B26","series-title":"BMC Pharmacol Toxicol","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40360-017-0168-z","article-title":"Short-term treatment with taurolidine is associated with liver injury","volume":"18","author":"Fahrmer R","year":"2017","unstructured":"Fahrmer R, M\u00f6ller A, Press AT, Kortgen A, Kiehntopf M, Ruchfuss F, . Short-term treatment with taurolidine is associated with liver injury. BMC Pharmacol Toxicol 2017; 18: 61.10.1186\/s40360-017-0168-z"},{"key":"B27","series-title":"Trends Cardiovasc Med","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.tcm.2016.03.014","article-title":"Amiodarone and dronedarone: An update","volume":"26","author":"Vamos M","year":"2016","unstructured":"Vamos M, Hohnloser SH. Amiodarone and dronedarone: An update. Trends Cardiovasc Med 2016; 26: 597\u2013602.2715581210.1016\/j.tcm.2016.03.014"},{"key":"B28","unstructured":"Access 10.01.2020 https:\/\/reference.medscape.com\/drug\/pacerone-cordarone-amiodarone-342296."},{"key":"B29","series-title":"Am J Health Syst Pharm","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/ajhp\/52.20.2340","article-title":"Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections","volume":"52","author":"Korth-Bradley JM","year":"1995","unstructured":"Korth-Bradley JM, Ludwig S. Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections. Am J Health Syst Pharm 1995; 52: 2340.856459610.1093\/ajhp\/52.20.2340"},{"key":"B30","series-title":"Int J Cardiol","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/j.ijcard.2008.12.158","article-title":"Incompatibility between intravenous amiodarone and heparin in an infant","volume":"145","author":"Bronzetti G","year":"2010","unstructured":"Bronzetti G, D\u2019Angelo C, Mariucci E, Picchio FM, Boriani G. Incompatibility between intravenous amiodarone and heparin in an infant. Int J Cardiol 2010; 145: e70\u20133.10.1016\/j.ijcard.2008.12.158"},{"key":"B31","series-title":"Braz J Anesthesiol","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0034-7094(13)70208-3","article-title":"Precipitation in Gallipoli: sugammadex\/amiodarone & sugammadex\/dobutamine & sugammadex\/protamine","volume":"63","author":"Hanc\u0131 V","year":"2013","unstructured":"Hanc\u0131 V, Kiraz HA, \u00d6m\u00fcr D, Ekin S, Uyan B, Yurtlu BS. Precipitation in Gallipoli: sugammadex\/amiodarone & sugammadex\/dobutamine & sugammadex\/protamine. Braz J Anesthesiol 2013; 63: 163\u20134.10.1016\/S0034-7094(13)70208-3"},{"key":"B32","series-title":"Clin Ther","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clinthera.2017.12.007","article-title":"Physical compatibility of meropenem and vaborbactam with select intravenous drugs during simulated Y-site administration","volume":"40","author":"Kidd JM","year":"2018","unstructured":"Kidd JM, Avery LM, Asempa TE, Nicolau DP, Kuti JL. Physical compatibility of meropenem and vaborbactam with select intravenous drugs during simulated Y-site administration. Clin Ther 2018; 40: 261\u20139.2929037410.1016\/j.clinthera.2017.12.007"},{"key":"B33","series-title":"Am J Health Syst Pharm","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2146\/ajhp110715","article-title":"Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration","volume":"70","author":"Fox LM","year":"2013","unstructured":"Fox LM, Wilder AG, Foushee JA. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health Syst Pharm 2013; 70: 520\u20134.2345640610.2146\/ajhp110715"},{"key":"B34","series-title":"Antimicrob Agents Chemother","first-page":"e00091","article-title":"A Novel nonantibiotic nitroglycerin-based catheter lock solution for prevention of intraluminal central venous catheter infections in cancer patients","volume":"61","author":"Chaftari AM","year":"2017","unstructured":"Chaftari AM, Hachem R, Szvalb A, Taremi M, Granwehr B, Viola GM, . A Novel nonantibiotic nitroglycerin-based catheter lock solution for prevention of intraluminal central venous catheter infections in cancer patients. Antimicrob Agents Chemother 2017; 61: e00091\u201317.28416559"},{"key":"B35","series-title":"Acta Anaesthesiol Scand","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1034\/j.1399-6576.1999.430712.x","article-title":"Halothane decreases bacterial adherence in vitro","volume":"43","author":"B\u00e1tai I","year":"1999","unstructured":"B\u00e1tai I, Ker\u00e9nyi M. Halothane decreases bacterial adherence in vitro. Acta Anaesthesiol Scand 1999; 43: 760\u20133.1045681710.1034\/j.1399-6576.1999.430712.x"},{"key":"B36","series-title":"J Mol Hist","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10735-012-9426-y","article-title":"Preconditioning with volatile anaesthetic in ischemic retinal lesion in rats","volume":"43","author":"Szabadfi K","year":"2012","unstructured":"Szabadfi K, Danyadi B, Manavalan S, Tamas A, Kiss P, Gabriel R, . Preconditioning with volatile anaesthetic in ischemic retinal lesion in rats. J Mol Hist 2012; 43: 565\u20139.10.1007\/s10735-012-9426-y"},{"key":"B37","series-title":"J Clin Anest","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jclinane.2016.09.011","article-title":"Atropine and glycopyrrolate do not support bacterial growth \u2013 safety and economic considerations","volume":"35","author":"Ittzes B","year":"2016","unstructured":"Ittzes B, Weiling Z, Batai IZ, Kerenyi M, Batai I. Atropine and glycopyrrolate do not support bacterial growth \u2013 safety and economic considerations. J Clin Anest 2016; 35: 560\u20133.10.1016\/j.jclinane.2016.09.011"},{"key":"B38","doi-asserted-by":"publisher","unstructured":"Access 15.01.2020 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/075955s015lbl.pdf.1045787410.1097\/00003643-199907000-00001","DOI":"10.1097\/00003643-199907000-00001"}],"container-title":["Acta Microbiologica et Immunologica Hungarica"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/67\/2\/article-p133.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/67\/2\/article-p133.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/67\/2\/article-p133.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T07:43:35Z","timestamp":1661759015000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/67\/2\/article-p133.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":38,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1556\/030.2020.01144","relation":{},"ISSN":["1217-8950","1588-2640"],"issn-type":[{"value":"1217-8950","type":"print"},{"value":"1588-2640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}